Metagenomi Therapeutics, Inc. MGX
1.15
0.00
0.00%
as of 25 Sep
- Market cap
- $43.4M
- P/E
- 0.0×
Follow MGX
Insider Buys
alert about insiders buying in the last 12 month
| Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.78 | 0.78 | 0.78 | 2.28 | 2.39 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
(1.70) | (1.70) | (1.70) | (4.54) | (2.56) |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.51 | 0.38 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.51 | 0.38 |
EV/Sales |
(4.60) | (4.60) | (4.60) | (1.89) | (2.78) |
EV/EBITDA |
2.46 | 2.46 | 2.46 | 1.08 | 0.75 |
EV/Operating CF |
2.25 | 2.25 | 2.25 | 0.91 | 0.79 |
EV/FCF |
2.03 | 2.03 | 2.03 | 0.88 | 0.78 |
Quick Ratio |
4.30 | 7.46 | 3.97 | 6.69 | 7.03 |
Current Ratio |
4.33 | 7.56 | 4.04 | 6.91 | 7.22 |
Net Debt/EBITDA |
3.33 | 8.17 | 3.25 | 2.72 | 1.71 |
Debt/Assets |
21.32% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.69 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.06 | 0.11 | 0.15 | 0.09 |
Operating CF/Net income |
(1.13) | (0.68) | 1.34 | 1.40 | 1.01 |
Capex/Depreciation |
(4.92) | (48.20) | 1.96 | 1.29 | (0.26) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 0.00% | 81.50% | 65.00% | (157.26%) | (44.67%) | |
| 0.00% | (15.67%) | (17.52%) | (22.64%) | (32.20%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(24.48%) | (13.02%) | (29.55%) | (32.74%) | (56.73%) |
Average Days of Receivables |
0.00 | 0.00 | 19.99 | 8.77 | 4.42 |
Research and Development Expense of Revenue |
5,958.02% | 250.81% | 210.93% | 208.78% | 374.59% |
Selling, General and Administrative Expense of Revenue |
3,996.71% | 108.73% | 64.45% | 61.22% | 106.27% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
154.32% | 11.41% | 15.47% | 30.99% | 47.02% |
Graham Net Nets |
3.66 | 3.66 | 3.66 | 1.41 | 1.71 |
Graham Number |
0.00 | 0.00 | 134.01 | 0.00 | 0.00 |
Earnings Yield |
(194.43%) | (194.43%) | (194.43%) | (72.58%) | (146.30%) |
Free Cash Flow Yield |
(288.34%) | (288.34%) | (288.34%) | (94.09%) | (148.19%) |
Revenue per Share |
0.07 | 5.06 | 13.14 | 1.58 | 0.68 |
Operating CF per Share |
7.45 | 8.74 | (26.85) | (3.30) | (2.39) |
Capex per Share |
(0.89) | (4.11) | (2.88) | (0.09) | (0.01) |
Free Cash Flow per Share |
6.55 | 4.63 | (29.73) | (3.40) | (2.40) |
Cash per Share |
33.20 | 106.51 | 79.64 | 7.52 | 4.32 |
Shareholders Equity per Share |
13.49 | 79.90 | 63.19 | 7.11 | 4.26 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
13.49 | 79.90 | 63.19 | 7.11 | 4.26 |
Free Cash Flow |
21.35 | 15.75 | (101.22) | (112.19) | (89.43) |
Working Capital |
83.74 | 318.36 | 209.41 | 220.65 | 142.61 |
Capital Expenditures |
(2.90) | (13.98) | (9.81) | (3.11) | (0.54) |
Net Current Asset Value |
10.88 | 224.09 | 128.61 | 168.22 | 103.03 |
EV/EBIT |
2.62 | 2.62 | 2.62 | 1.11 | 0.73 |
Capex to Sales |
11.95 | 0.81 | 0.22 | 0.06 | 0.02 |
Net Profit Margin |
(8,823.87%) | (253.45%) | (152.50%) | (149.26%) | (348.54%) |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||
Depreciation/Fixed assets |
0.15 | 0.02 | (0.23) | (0.14) | 0.17 |
Cash ROIC |
11.18% | 2.08% | (23.22%) | (26.25%) | (31.68%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 28.21 | 32.28 |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
— | — | — | 1.85 | 0.78 |
Average Payables |
— | 1.68 | 1.90 | 1.16 | 1.01 |
Average Assets |
— | 278.24 | 389.66 | 344.72 | 272.85 |
Average Common Equity |
— | (53.49) | (105.01) | 49.64 | 196.73 |
Columns are period end dates